Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome
Noriyoshi Iriyama(Nihon University), Tomoki Naoe(National Hospital Organization), Toru Sakura(Gunma Saiseikai Maebashi Hospital), Masatomo Takahashi(Shiga University of Medical Science), Sumihisa Honda(Nagasaki University), Kazunori Ohnishi(Hamamatsu University School of Medicine), Tomoya Maeda(Saitama Medical University), Yoshihiro Hatta(Nihon University), Yukio Kobayashi(National Cancer Center Hospital East), Shinya Sato(Tokuyama (Japan)), Hiroshi Handa(Gunma University), Yasushi Miyazaki(Nagasaki University), Hisashi Sakamaki(Tokyo Metropolitan Komagome Hospital), Tomohiko Taki(Kyorin University), Shunichiro Yamaguchi(Kumamoto University), Shuichi Miyawaki(Tokyo Metropolitan Ohtsuka Hospital), Norio Asou(Saitama Medical University), Masafumi Taniwaki(Kyoto Prefectural University), Shigeki Ohtake(Kanazawa University)
Cited by 12
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k